Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/10948
Title: Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial.
Authors: Tebbutt, Niall C;Cummins, M M;Sourjina, T;Strickland, A;Van Hazel, G;Ganju, V;Gibbs, D;Stockler, M;Gebski, V;Zalcberg, John R
Institutional Author: Australasian Gastro-Intestinal Trials Group
Affiliation: Department of Medical Oncology, Austin Health, PO Box 5555, Studley Road, Heidelberg, Melbourne, Victoria 3084, Australia. niall.tebbutt@ludwig.edu.au
Issue Date: 12-Jan-2010
Citation: British Journal of Cancer 2010; 102(3): 475-81
Abstract: Docetaxel administered 3-weekly with cisplatin and 5-fluorouracil leads to better survival than does standard therapy in patients with oesophagogastric cancer, but leads to high rates of haematological toxicity. Weekly docetaxel is associated with less haematological toxicity. This randomised phase II study tested weekly docetaxel-based combination chemotherapy regimens, with the aim of maintaining their activity while reducing toxicity.Patients with histologically confirmed metastatic oesophageal or gastric carcinoma were randomised to receive weekly docetaxel (30 mg m(-2)) on days 1 and 8, cisplatin (60 mg m(-2)) on day 1, and 5-fluorouracil (200 mg m(-2) per day) continuously, every 3 weeks (weekly TCF, wTCF); or docetaxel (30 mg m(-2)) on days 1 and 8 and capecitabine (1600 mg m(-2) per day) on days 1-14, every 3 weeks (weekly TX, wTX).A total of 106 patients were enrolled (wTCF, n=50; wTX, n=56). Response rates, the primary end point, were 47% with wTCF and 26% with wTX. Rates of febrile neutropenia were low in each arm. Median progression-free and overall survival times were 5.9 and 11.2 months for wTCF and 4.6 and 10.1 months for wTX, respectively.Weekly TCF and TX have encouraging activity and less haematological toxicity than TCF administered 3-weekly. Weekly docetaxel-based combination regimens warrant further evaluation in this disease.
Internal ID Number: 20068567
URI: http://ahro.austin.org.au/austinjspui/handle/1/10948
DOI: 10.1038/sj.bjc.6605522
URL: http://www.ncbi.nlm.nih.gov/pubmed/20068567
Type: Journal Article
Subjects: Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols.adverse effects.therapeutic use
Cisplatin.administration & dosage
Deoxycytidine.administration & dosage.analogs & derivatives
Esophageal Neoplasms.drug therapy.mortality.psychology
Female
Fluorouracil.administration & dosage.analogs & derivatives
Humans
Male
Middle Aged
Quality of Life
Stomach Neoplasms.drug therapy.mortality.psychology
Taxoids.administration & dosage
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.